Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| KonaTel, Inc.DALP · Entity 8122 | Director | July 19, 2017 | August 02, 2017 |
| Silo Pharma, Inc.SILO · Entity 8320 | Chief Financial Officer | May 23, 2025 | May 27, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
KonaTel, Inc.
Report date July 19, 2017 · Filed August 02, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 50,000 |
Reported balance
After 2017-07-25 transaction · row 1
1 source rowRow 1 · 2017-07-25 · Grant · Acquired 50,000 · Balance 50,000 F1: These shares were compensatory shares for services as a director valued at $1,690. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were compensatory shares for services as a director valued at $1,690.
Silo Pharma, Inc.
Report date May 23, 2025 · Filed May 27, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.43 · Expires 2035-05-23 | Direct | 55,000 |
Reported balance
After 2025-05-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-05-23 · Grant · Acquired 50,000 · Balance 55,000 F1: The options were issued pursuant to the Issuer's 2020 Omnibus Equity Incentive Plan and one hundred percent (100%) of the shares subject to the option shall vest on the one (1)-year anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The options were issued pursuant to the Issuer's 2020 Omnibus Equity Incentive Plan and one hundred percent (100%) of the shares subject to the option shall vest on the one (1)-year anniversary of the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 23, 2025 Filed May 27, 2025 19:02 UTC | Silo Pharma, Inc. SILO · Entity 8320 | GrantOptions (right to buy) · Derivative | 50,000 | $0.00 Strike: $0.43 | $0.00 |
DisclosureSEC source: 0001213900-25-047913 · ownership.xml · derivative · entry 1 Ryweck Daniel E. · CIK 0001652799 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 50,000 shares Expires 2035-05-23 F1 · kind: The options were issued pursuant to the Issuer's 2020 Omnibus Equity Incentive Plan and one hundred percent (100%) of the shares subject to the option shall vest on the one (1)-year anniversary of the date of grant. Read SEC document |
| May 26, 2023 Filed May 26, 2023 16:17 UTC | Silo Pharma, Inc. SILO · Entity 8320 | PurchaseCommon Stock | 1,000 | $2.13 | $2,126.40 |
DisclosureSEC source: 0001213900-23-043531 · ownership.xml · nonDerivative · entry 1 Ryweck Daniel E. · CIK 0001652799 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Read SEC document |
| July 25, 2017 Filed Aug 2, 2017 21:11 UTC | KonaTel, Inc. DALP · Entity 8122 | GrantCommon Stock | 50,000 | $0.03 | $1,690.00 |
DisclosureSEC source: 0001010412-17-000042 · primary_doc.xml · nonDerivative · entry 1 Ryweck Daniel E. · CIK 0001652799 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 F1 · kind: These shares were compensatory shares for services as a director valued at $1,690. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.